← 治験一覧に戻る
遺伝性血管性浮腫患者におけるナベニバートの研究
基本情報
- NCT ID
- NCT06842823
- ステータス
- 募集中
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 145
- 治験依頼者名
- Astria Therapeutics, Inc.
概要
This is a Phase 3 multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of subcutaneous administration of navenibart in adult and adolescent participants with type 1 or type 2 hereditary angioedema (HAE). The goal of this clinical trial is to evaluate the efficacy and safety of navenibart compared to placebo in preventing HAE attacks in participants with HAE.
対象疾患
Hereditary Angioedema (HAE)
介入
navenibart(DRUG)
Placebo(DRUG)
依頼者（Sponsor）
Astria Therapeutics(INDUSTRY)